Advertisement

Tumor Biology

, Volume 37, Issue 2, pp 2473–2480 | Cite as

LIM domain only 2 induces glioma invasion via cytosolic p27KIP1

Original Article

Abstract

High-grade gliomas are considered the most malignant of brain tumors and have a poor prognosis. In a previous study, we showed that LIM domain only 2 (LMO2) regulates glioma stem cell properties and tumor angiogenesis and gave rise to highly invasive glioma xenografts. Glioma invasion in the surrounding parenchymal tissues is a major hurdle with respect to eliminating glioma by surgery. Invasive glioma cells are considered one of the main culprits for the recurrence of tumors after therapies. In the current study, we focused on determining the molecular mechanism(s) by which LMO2 regulates glioma cell migration and invasion. Forced expression of LMO2 in human U87MG glioma cells led to glioma invasion, as determined by in vivo xenograft assays and enhanced in vitro migration and invasion. LMO2 was associated with increased levels of cytosolic p27Kip1 protein. LMO2 possibly induced the stabilization and augmented interactions between p27Kip1 and RhoA. We knocked down the expression of p27Kip1, which led to a decrease in LMO2-driven glioma cell migration and invasion. Taken together, our findings indicate that LMO2 promotes glioma cell migration and invasion by increasing the levels of cytosolic p27Kip1.

Keywords

Cell invasion Cell migration Glioma LMO2 p27Kip1 RhoA 

Notes

Acknowledgments

We are grateful to all members of the Cell Growth Regulation Laboratory for their helpful discussion and technical assistance. This work was supported by grants from Next-Generation Biogreen21 Program (PJ01107701) and the National Research Foundation of Korea (NRF) and the Ministry of Education, Science, and Technology of Korea (2011–0017544).

Conflicts of interest

None

References

  1. 1.
    Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.CrossRefPubMedGoogle Scholar
  2. 2.
    Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10:319–31.CrossRefPubMedGoogle Scholar
  3. 3.
    Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother. 2009;9:519–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst. 2007;99:1583–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neuro-Oncol. 2011;101:319–23.CrossRefGoogle Scholar
  6. 6.
    Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008;9:446–54.CrossRefPubMedGoogle Scholar
  7. 7.
    Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol. 2004;265:23–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Abraham MT, Kuriakose MA, Sacks PG, Yee H, Chiriboga L, Bearer EL, et al. Motility-related proteins as markers for head and neck squamous cell cancer. Laryngoscope. 2001;111:1285–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003;9:2632–41.PubMedGoogle Scholar
  10. 10.
    Yan B, Chour HH, Peh BK, Lim C, Salto-Tellez M. RhoA protein expression correlates positively with degree of malignancy in astrocytomas. Neurosci Lett. 2006;407:124–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res. 2006;66:9535–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Valge-Archer VE, Osada H, Warren AJ, Forster A, Li J, Baer R, et al. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Proc Natl Acad Sci U S A. 1994;91:8617–21.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wadman I, Li J, Bash RO, Forster A, Osada H, Rabbitts TH, et al. Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia. EMBO J. 1994;13:4831–9.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Grutz GG, Bucher K, Lavenir I, Larson T, Larson R, Rabbitts TH. The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells. EMBO J. 1998;17:4594–605.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Xu Z, Huang S, Chang LS, Agulnick AD, Brandt SJ. Identification of a TAL1 target gene reveals a positive role for the LIM domain-binding protein Ldb1 in erythroid gene expression and differentiation. Mol Cell Biol. 2003;23:7585–99.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gering M, Yamada Y, Rabbitts TH, Patient RK. Lmo2 and Scl/Tal1 convert non-axial mesoderm into haemangioblasts which differentiate into endothelial cells in the absence of Gata1. Development. 2003;130:6187–99.CrossRefPubMedGoogle Scholar
  17. 17.
    Mead PE, Deconinck AE, Huber TL, Orkin SH, Zon LI. Primitive erythropoiesis in the Xenopus embryo: the synergistic role of LMO-2 SCL and GATA-binding proteins. Development. 2001;128:2301–8.PubMedGoogle Scholar
  18. 18.
    Pardanaud L, Yassine F, Dieterlen-Lievre F. Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny. Development. 1989;105:473–85.PubMedGoogle Scholar
  19. 19.
    Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin e-cdk2 is a regulator of p27kip1. Genes Dev. 1997;11:1464–78.CrossRefPubMedGoogle Scholar
  20. 20.
    Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, et al. A growth factor-dependent nuclear kinase phosphorylates p27(kip1) and regulates cell cycle progression. EMBO J. 2002;21:3390–401.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Connor MK, Kotchetkov R, Cariou S, Resch A, Lupetti R, et al. Crm1/ran-mediated nuclear export of p27(kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell. 2003;14:201–13.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Larrea MD, Liang J, Da Silva T, Hong F, Shao SH, et al. Phosphorylation of p27kip1 regulates assembly and activation of cyclin d1-cdk4. Mol Cell Biol. 2008;28:6462–72.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 2004;18:862–76.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kim SH, Kim EJ, Hitomi M, Oh SY, Jin X, Jeon HM, et al. The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells. Cell Death Differ. 2015;22:1517–25.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Jin X, Jin X, Sohn YW, Yin J, Kim SH, Joshi K. Blockade of EGFR signaling promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27(KIP1) and MMP3 expression. Cancer Lett. 2013;328:235–42.CrossRefPubMedGoogle Scholar
  26. 26.
    Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11:1475–89.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kim JK, Jin X, Sohn YW, Jin X, Jeon HY, Kim EJ, et al. Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling. Cancer Lett. 2014;353:194–200.CrossRefPubMedGoogle Scholar
  28. 28.
    Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, et al. Pkb/akt mediates cell-cycle progression by phosphorylation of p27(kip1) at threonine 157 and modulation of its cellular localization. Nat Med. 2002;8:1145–52.CrossRefPubMedGoogle Scholar
  29. 29.
    Viglietto G, Motti ML, Bruni P, Melillo RM, D’Alessio A, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(kip1) by pkb/akt-mediated phosphorylation in breast cancer. Nat Med. 2002;8:1136–44.CrossRefPubMedGoogle Scholar
  30. 30.
    Parker KK, Brock AL, Brangwynne C, Mannix RJ, Wang N, Ostuni E, et al. Directional control of lamellipodia extension by constraining cell shape and orienting cell tractional forces. FASEB J. 2002;16:1195–204.CrossRefPubMedGoogle Scholar
  31. 31.
    Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3:362–74.CrossRefPubMedGoogle Scholar
  32. 32.
    Viglietto G, Motti ML, Fusco A. Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle. 2002;1:394–400.CrossRefPubMedGoogle Scholar
  33. 33.
    Motti ML, De Marco C, Califano D, Fusco A, Viglietto G. Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer. Cell Cycle. 2004;3:1074–80.CrossRefPubMedGoogle Scholar
  34. 34.
    Sekimoto T, Fukumoto M, Yoneda Y. 14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27(Kip1). EMBO J. 2004;23:1934–42.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Biotechnology, School of Life Science and BiotechnologyKorea UniversitySeoulRepublic of Korea
  2. 2.Institute of Animal Molecular BiotechnologyKorea UniversitySeoulRepublic of Korea
  3. 3.Department of Neurological Surgery, James Comprehensive Cancer CenterThe Ohio State UniversityColumbusUSA
  4. 4.Department of Biochemistry, College of MedicineHallym UniversityChuncheonRepublic of Korea

Personalised recommendations